Home — GMP Manufacturing
GMP Manufacturing · CDMOFrom your molecule to a GMP batch.
Theertha brings mammalian and microbial manufacturing together with the development, analytical and quality teams behind it — a single contract manufacturing partner for companies that need biologics made to a standard they can file.
Manufacturing, as an extension of your team
Theertha’s GMP manufacturing is built for companies that would rather partner than build. We take a defined process — yours, or one we develop with you — and carry it to a documented, release-tested batch, with process development, analytical and quality working alongside the plant rather than in separate silos.
That integration is the point. Clone development, process and analytical understanding and the manufacturing floor live under one roof, so technology transfer is short, the data trail is continuous, and every batch leaves with the package a regulator expects to see.
Whether you need a single clinical lot, a comparability batch for a biosimilar, or ongoing supply of a high-value product, we scale the engagement to the programme — and we tell you honestly what we can accelerate and where the real risk in your timeline sits.
Talk to us about your programme- Two production lines 2,000 L mammalian cell culture and 50 L microbial fermentation.
- End to end Upstream, downstream, fill–finish, analytical and QC under one roof.
- Multi-modality Monoclonal antibodies, biosimilars, plasmid DNA, recombinant and high-value products.
- Documentation-first Every batch and method released with its evidence attached.
- Bengaluru, India In the KIADB Bommasandra–Jigani biotech corridor.
Development, analytical, quality and manufacturing on one site.
Senior leaders with 25+ years each across biosimilars, characterization and quality.
Every batch and method released with its evidence attached.
Development evidence structured for your intended market.
Two production lines, built for biologics.
Dedicated mammalian and microbial capacity — at a scale matched to clinical and early-commercial supply.
Monoclonal antibodies & plasmid DNA
A 2,000 litre mammalian line carrying the seed train through to a production bioreactor, for therapeutic monoclonal antibodies and plasmid DNA at pilot and clinical scale.
Clinical material & high-value products
A 50 litre microbial fermentation line for clinical-grade material generation and other high-value recombinant products, with process control batch to batch.
Engineered end to end.
Your process carried from the seed train to a release-tested batch — one continuous, documented workflow under one roof.
Cell culture and fermentation, seed to scale.
Upstream is where titre, product quality and consistency are set. We run both mammalian cell culture and microbial fermentation, carrying the seed train through to the production bioreactor with monitored, controlled parameters at every step.
Media and feed strategies are optimised for the molecule, and the process is designed for the hand-off to downstream — so recovery and purification start from a well-characterised harvest.
- Mammalian cell culture — 2,000 L Seed train through a 2,000 L production bioreactor for monoclonal antibodies and plasmid DNA.
- Microbial fermentation — 50 L Fermentation for clinical-grade material and high-value recombinant products.
- Media & feed strategy Defined media and feeding optimised for titre, product quality and batch-to-batch consistency.
- Process monitoring & control Controlled culture parameters and in-process checks across the run.
From harvest to high-purity drug substance.
Downstream turns a harvest into a high-purity, well-characterised drug substance. Our purification is anchored on multi-column chromatography using an ÄKTA Pilot 600 system, with the orthogonal steps a biologic needs to meet its quality profile.
Tangential-flow filtration handles concentration and buffer exchange, and filtration steps manage bioburden and deliver a clean drug substance ready for formulation.
- Harvest & clarification Recovery and clarification of the target molecule from the bioreactor.
- Chromatography Multi-column purification on an ÄKTA Pilot 600 — affinity, ion-exchange and polishing steps.
- Tangential-flow filtration Concentration and buffer exchange to the target formulation.
- Filtration & bioburden control Reduction and sterile filtration into drug substance.
Drug substance to drug product.
Formulation is treated as part of the product, not an afterthought. We develop the excipient and buffer system that keeps the molecule stable, then fill the drug product under controlled conditions.
Forced-degradation and stability studies run alongside, so the shelf-life and storage story is built on data rather than assumption.
- Formulation development Excipient and buffer screening for stability and deliverability.
- Filling Controlled filling of drug product for clinical and early-commercial supply.
- Stability Forced-degradation and stability studies supporting shelf life and storage.
Modalities on one site.
Therapeutic biologics and high-value recombinant products, from a single integrated partner.
Monoclonal antibodies
Therapeutic monoclonal antibodies on the mammalian platform, from clone to release-tested batch.
Biosimilars
Comparability-oriented development and manufacturing for biosimilar programmes.
Plasmid DNA
Plasmid DNA production to support advanced-therapy and research programmes.
Recombinant proteins
Microbial expression of recombinant proteins and enzymes at clinical scale.
High-value products
Specialised, high-value recombinant products where purity and consistency are critical.
Every batch, characterised and released.
Material without data is a sample, not a supply. Our analytical and QC capability sits beside manufacturing, so every batch is characterised and released against agreed specifications on validated or qualified methods.
Orthogonal characterization supports comparability and regulatory review — the evidence a partner audit or a dossier will ask for.
- Instrumentation HPLC, UPLC, capillary electrophoresis, RT-PCR and ELISA.
- Characterization Identity, purity, potency and product-quality attributes.
- Release & stability testing Against agreed specifications, on validated or qualified methods.
- Comparability Orthogonal characterization for comparability and bridging.
A partner you can file behind.
A defined quality management system, and a documentation package built for review.
Quality management
- Quality system Document control, deviation and CAPA, change management, supplier qualification and internal audit.
- Data integrity ALCOA+ principles across records and instrument data, with audit trails.
- Audit & inspection readiness Structured, retrievable documentation so reviews move quickly and predictably.
- Regulatory support Evidence structured for the intended market, with support for US, EU and India.
What you receive
- Certificate of Analysis Issued per batch, against agreed specifications.
- Executed batch records Complete, contemporaneous batch documentation.
- Method validation reports Development, qualification and validation of analytical methods.
- Stability data Where in scope, supporting shelf life and storage.
- SOPs & protocols For technology transfer in and out.
The work around the batch.
Take one step, or the whole chain — the deliverable is working material and the documentation that lets you use it.
Process development
Upstream and downstream development engineered for titre, recovery and a comparability-ready quality profile.
Analytical development
Method development, qualification and validation with orthogonal product characterization.
Technology transfer
Documentation-first transfer of processes and methods, in from you or out to your site.
Scale-up
Bench to pilot and clinical scale, with the data trail carried through.
Clinical & early-commercial supply
Batches sized and documented for clinical programmes and early supply.
Formulation & stability
Formulation development with forced-degradation and stability studies.
Built to give you confidence.
Integrated with development
Process, analytical and quality teams sit beside the plant — short transfer, a continuous data trail.
GMP-grade, documentation-first
Every batch and method leaves the building with its evidence attached.
Mammalian and microbial
Antibodies, plasmid DNA and microbial high-value products on one site.
Led by people who have filed
Senior scientists with decades across biosimilars, characterization and quality — the people on your calls.
Comparability-ready
An analytical package designed for comparability and regulatory review.
Bengaluru base
India’s densest biotech corridor, with validated cold-chain and global logistics.
From first call to released batch.
A simple, predictable path — we tell you early what fits and what doesn’t.
Enquiry
Share the molecule, stage, scale and timeline. We sign an NDA and review it with the right people.
Scope & feasibility
We assess the process, confirm the fit to our lines, and flag the real risks in the timeline.
Proposal
A plan, a timeline and a quote — scoped to one batch or ongoing supply.
Technology transfer
Documented transfer of the process and methods, in from you or developed with you.
Manufacturing
GMP production on the agreed line, with in-process controls and a continuous record.
Release & delivery
QC release against specification, delivered with the full documentation package.
What partners ask us.
What scales can you manufacture at?
A 2,000 litre mammalian cell-culture line and a 50 litre microbial fermentation line, at pilot and clinical scale. We size the batch to your programme rather than forcing it to a fixed lot size.
Which modalities do you manufacture?
Monoclonal antibodies, biosimilars, plasmid DNA, recombinant proteins and other high-value recombinant products — mammalian and microbial, on one site.
Do you support process development and technology transfer?
Yes. Process development, analytical development and quality work alongside manufacturing, with documented technology transfer in from you or out to your site. The teams that develop the process are the teams that run it.
What documentation do we receive?
A Certificate of Analysis per batch, executed batch records, method development, qualification and validation reports, stability data where in scope, and the SOPs and protocols needed for technology transfer.
Which markets is the evidence prepared for?
Development and manufacturing evidence is structured for the intended market, with support for US, EU and India submissions and for partner audits and regulatory queries.
Is our information kept confidential?
Yes. Every programme is handled under a confidentiality agreement. Your materials, processes and data remain yours, start to finish.

Bring us your molecule and your timeline.
Tell us the stage, the scale and the deadline. We will come back with a technically sound path to clinical-grade material — and the documentation that lets you use it.